{
    "clinical_study": {
        "@rank": "132894", 
        "arm_group": {
            "arm_group_label": "JX-594 IV Infusion", 
            "arm_group_type": "Experimental", 
            "description": "Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594"
        }, 
        "brief_summary": {
            "textblock": "This is a single-arm open-label Phase 2 study in patients with peritoneal carcinomatosis of\n      ovarian origin that are not eligible for curative treatments. Patients will receive 5 weekly\n      IV infusions of JX-594 until radiographically determined progressive disease. Patients will\n      be allotted in a 1:1 ratio to undergo a laparoscopy and tumor biopsy 10 days after dose 1 or\n      10 days after Dose 5. Patients will be monitored on study until evidence of progression or\n      death or for 12 months post treatment."
        }, 
        "brief_title": "Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single-arm open-label Phase 2 study in patients with peritoneal carcinomatosis of\n      ovarian origin that are not eligible for curative treatments. Patients will receive 5 weekly\n      IV infusions of JX-594 and will continue to receive IV infusion of JX-594 every 3 weeks\n      until radiographically determined progressive disease. Using a 2 stage trial design, if 2 or\n      more of the first 15 patients show a clinical response as defined by Response Evaluation\n      Criteria in Solid Tumors 1.10 criteria (or if 3 of the 15 have stable disease as defined by\n      Modified Response Evaluation Criteria in Solid Tumors 1.1 or clinically), the arm will be\n      expanded to a total of 25 patients (Stage 2).\n\n      In Stage 1, patients will be allotted in a 1:1 ratio to undergo a laparoscopy and tumor\n      biopsy 10 days after dose 1 or 10 days after Dose 5. A decision as to whether laparoscopy\n      will be performed in Stage 2 will be reached at the conclusion of Stage 1.\n\n      Patients will be monitored on study until evidence of progression or death or for 12 months\n      post treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed ovarian carcinomatosis with; no curative treatment options\n             available, or the patient has refused or cannot tolerate the standard therapy.\n             Patients must have had prior primary platinum based chemotherapy.\n\n          2. Radiologically evaluable disease.\n\n          3. At least 2 tumor masses amenable to biopsy (excisional or core) or laparoscopy. Tumor\n             masses selected cannot be followed by Response Evaluation Criteria in Solid Tumors\n             1.1.\n\n          4. Expected survival \u226512 weeks\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          6. Women aged \u226518 years\n\n          7. Sexually active patients must be able and willing to abstain for a minimum of 15 days\n             after treatment with JX-594 and subsequently use barrier method for at least 6 weeks\n             after the last JX-594 treatment\n\n          8. Signed informed consent form\n\n          9. No contraindications to undergo general anesthetic or laparoscopy.\n\n         10. Laboratory requirements:\n\n        Hematology\n\n          -  Absolute neutrophil count (ANC) \u22651.0 x 109/L\n\n          -  Lymphocytes \u22650.5 x109/L\n\n          -  Hemoglobin \u226590 g/L (correction with transfusion or erythropoietin based therapy\n             allowed)\n\n          -  Platelet count \u226575 x 109/L\n\n        Biochemistry\n\n          -  Total bilirubin \u22641.5 x upper limit of normal (ULN)\n\n          -  Alkaline Phosphatase (ALP), Aspartate transaminase (AST), alanine aminotransferase\n             (ALT) \u22643 x ULN (if patient exhibits liver metastasis, up to 5 x ULN acceptable)\n\n          -  Serum creatinine \u22641.5 x ULN or creatinine clearance is \u22651.0 mL/s according to\n             Cockroft-Gault formula\n\n          -  International normalized ratio (INR) \u22641.5 Serum chemistries within normal limits\n             (WNL) or Grade 1 (with exception of sodium, potassium, glucose, calcium,\n             phosphate,magnesium, chloride upon Investigator discretion)\n\n        Exclusion Criteria:\n\n          1. Significant immunodeficiency due to underlying illness (e.g., known HIV/AIDS) and/or\n             medication (e.g., systemic corticosteroids taken for more than 4 weeks within the\n             preceding 3 months). Intermittent doses of corticosteroids as an antiemetic for\n             chemotherapy are acceptable. Patients have to be off continuous steroids for at least\n             4 weeks\n\n          2. Therapeutic anticoagulant therapy\n\n          3. History of severe exfoliative skin condition (e.g., eczema or ectopic dermatitis\n             requiring systemic therapy for more than 4 weeks)\n\n          4. Tumor(s) invading a major vascular structure (e.g., carotid artery)\n\n          5. Clinically significant and uncontrolled pericardial or pleural effusions\n\n          6. Severe or unstable cardiac disease, including significant coronary artery disease\n             (e.g., requiring angioplasty or stenting) within the preceding 12 months, unless\n             well-controlled and on stable medical therapy for at least 3 months\n\n          7. Tumor burden >50% of abdominal cavity or malignant obstruction of small bowel or\n             other condition that would preclude safe biopsy or laparoscopy\n\n          8. Brain metastasis: Viable central nervous system (CNS) malignancy associated with\n             clinical symptoms (Note: enrollment allowed if completely resected or stable post\n             radiotherapy >12 weeks).\n\n          9. Received anti-cancer therapy within 4 weeks prior to first treatment (6 weeks in case\n             of mitomycin C or nitrosoureas)\n\n         10. Prior participation in other research protocol involving an investigational product\n             within 4 weeks or 5 half-lives, whichever is longer, prior to first treatment\n\n         11. Medical condition, laboratory abnormality or active infection that in the judgment of\n             the Principal Investigator may increase the risk associated with study participation\n             or may prevent laparoscopy or may interfere with interpretation of study results\n             and/or otherwise make the patient inappropriate for study entry\n\n         12. Use of interferon/pegylated interferon (PEG-IFN) or ribavirin that cannot be\n             discontinued within 14 days prior to any JX-594 dose. (Note: please consult Ozmosis\n             Research Inc. if patient is taking any other anti-viral medications to determine\n             eligibility)\n\n         13. Unable to receive IV contrast for CT scanning due to documented history of iodinated\n             contrast allergy unless controlled by medical intervention (e.g., premedication with\n             steroids, diphenhydramine, or other anti-allergic medications)\n\n         14. Pregnant or nursing an infant\n\n         15. Pulse oximetry O2 saturation <90% at rest on room air\n\n         16. Experienced a severe systemic reaction or side-effect as a result of a previous\n             smallpox vaccination."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017678", 
            "org_study_id": "OZM-044"
        }, 
        "intervention": {
            "arm_group_label": "JX-594 IV Infusion", 
            "description": "5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.", 
            "intervention_name": "JX-594", 
            "intervention_type": "Biological", 
            "other_name": "vaccinia virus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "JX-594", 
            "Ovarian cancer", 
            "Peritoneal", 
            "Carcinomatosis", 
            "Vaccinia virus", 
            "Oncolytic virus"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "Gerry.Prendergast@uhn.ca", 
                "last_name": "Gerry Prendergast, R.N.", 
                "phone": "416-946-4501", 
                "phone_ext": "4365"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario"
                }, 
                "name": "Princess Margaret Cancer Center"
            }, 
            "investigator": {
                "last_name": "Helen McKay", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label, Phase 2 Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by 5 Weekly Intravenous (IV) Infusions in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin", 
        "overall_contact": {
            "email": "Gerry.Prendergast@uhn.ca", 
            "last_name": "Gerry Prendergast, R.N.", 
            "phone": "416-946-4501", 
            "phone_ext": "4365"
        }, 
        "overall_official": [
            {
                "affiliation": "Mount Sinai Hospital, New York", 
                "last_name": "Judith Andrea McCart, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Princess Margaret Cancer Centre", 
                "last_name": "Helen MacKay, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine radiographic response rate (response evaluation criteria in solid tumors [modified Response Evaluation Criteria in Solid Tumors 1.1])to JX-595", 
            "measure": "Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017678"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mount Sinai Hospital, Canada", 
            "investigator_full_name": "Andrea McCart", 
            "investigator_title": "Gastrointestinal Surgical Oncologist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Collection of incidence(s) of treatment-emergent adverse events will be tabulated and stratified by severity and relationship to JX-594 administration", 
                "measure": "Assessment of Adverse Events related to JX-594 administered by repetitive IV infusion", 
                "safety_issue": "Yes", 
                "time_frame": "Weekly"
            }, 
            {
                "description": "Determine response rate using modified immune criteria in ovarian peritoneal carcinomatosis", 
                "measure": "Response rate using modified immune criteria", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Determine the delivery of JX-594 to solid tumors after repetitive IV infusion in patients with peritoneal carcinomatosis", 
                "measure": "Delivery of JX-594 in solid tumours", 
                "safety_issue": "No", 
                "time_frame": "Weekly"
            }, 
            {
                "description": "Determine the pharmacokinetics of JX-594 by examining secondary replication of viral genomes in blood over time.", 
                "measure": "JX-594 Secondary Replication in blood over time", 
                "safety_issue": "No", 
                "time_frame": "Weekly"
            }, 
            {
                "description": "Determine the immune response to JX-594 by change in peripheral white blood cell counts over time", 
                "measure": "Immune response to JX-594", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Determine serum tumor marker response rate", 
                "measure": "Response of tumour markers to JX-594", 
                "safety_issue": "No", 
                "time_frame": "Weekly"
            }, 
            {
                "description": "Determine time to progression of disease after JX-594 administration", 
                "measure": "Time to progressive disease", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Mount Sinai Hospital, Canada", 
        "sponsors": {
            "collaborator": {
                "agency": "Ontario Institute for Cancer Research (OICR)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Andrea McCart", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}